BASF opens new GMP Solution Center in Michigan
BASF opens its new Good Manufacturing Practice (GMP) Solution Center, in Wyandotte, Michigan. This investment underscores the ongoing commitment of BASF to providing innovative solutions in the biopharma and pharmaceutical ingredients industries, including the reliable supply of bioprocessing ingredients and excipients for biopharma applications as well as small molecules.
This new facility will play a crucial role in the expansion of BASF's existing network of GMP sites, with innovative systems and processes that ensure products are produced consistently and controlled according to high quality standards. These practices are crucial in the pharmaceutical industry, where the quality of products is paramount for safety and efficacy.
Featuring state-of-the-art clean room packaging, and high-sensitivity analytical testing, this new facility enables close collaboration with customers on customized chemistries for product development. Additionally, improved manufacturing capabilities will allow for more tightly controlled parameters beyond compendial limits and a validated control system that allows for high reproductivity.
Marion Kuhn, vice president of business management, BASF Pharma Solutions states, 'Our new GMP Solution Center exemplifies BASF's dedication to understanding and addressing the evolving needs of our customers in both the biopharma and pharmaceutical industries. This state-of-the-art facility will play a fundamental role in enabling us to collaborate closely with our customers worldwide on product development and GMP manufacturing in ways that are unique to the industry, further strengthening our position as an innovator in the pharmaceutical sector.'
'Wyandotte's new GMP Solution Center is a key example of BASF's commitment to innovative excellence,' said Benjamin Knudsen, vice president of research North America at BASF Corporation. 'This expansion not only showcases our dedication to developing customized solutions, but it also highlights our ability to adapt and innovate in response to our customers' needs. Together, we are paving the way for new innovative solutions.' Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged.
BASF has opened a new GMP Solution Center in Wyandotte, Michigan, enhancing its support for the biopharma and pharmaceutical industries. The facility features clean room packaging, advanced testing, and custom chemistry development. It strengthens BASF's global GMP network and commitment to high-quality, innovative solutions and close customer collaboration.
Fibre2Fashion News Desk (HU)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
With no upgradation plan, several small drug companies may shut operations
New Delhi: Thousands of pharmaceutical companies in the micro, small and medium enterprise (MSME) sector face the grim prospect of closure, having passed the May-end deadline for submitting plans to the government for upgrading their manufacturing facilities. Only a fraction of such units, 1,700 out of an estimated 6,000, have submitted plans for upgradation as per the newly-notified Good Manufacturing Practices ( GMP ), people in the know told ET. Industry executives said they anticipate many units to shut down and thousands of job losses as these units struggle with high costs needed to make the necessary infrastructure improvements. The government, meanwhile, is likely to initiate site audits and kick-off regulatory action against those not complying with the new standards, the people said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 혈압, 혈당, 고지혈로 고민이 많으신 분들만 읽어주세요. 메디셜 더 읽기 Undo Experts noted that if the government takes stringent action, it may cause drug shortages in areas like cancer, where there are fewer manufacturing units. Live Events "Next few months will see a lot of small sector units getting closed, resulting in increased unemployment. The upgradation requirement to Schedule M has created challenges for small and medium units potentially leading to closures and unemployment," said an industry executive, raising concerns about the future of these units. Some executives believe that 'stop production notices' will be issued to units not complying with the newly-notified standards, which may inflate drug prices. "These units require hand holding by the government and if they do not get further support, then production will stop, resulting in escalation of drug prices," a second executive said. Health ministry officials however stressed that sufficient time has been given to the industry for complying with the new norms. Earlier the ministry had received several representations from pharma associations with annual revenues of less than '250 crore for extension of timeline for the implementation of revised Schedule M. Schedule M of the Drugs and Cosmetics Act outlines quality standards for pharma products. To address their concerns, in February, the ministry issued another notification for extension of implementation of revised Schedule M whereby manufacturers with less than Rs 250 crore revenues were required to file an application to the Central License Approving Authority within three months, along with the plan of upgradation.
The Hindu
5 hours ago
- The Hindu
Glenmark Pharma's North Carolina facility gets five U.S. FDA observations
The U.S. Food and Drug Administration (FDA) has issued a Form 483 with five observations to Glenmark Pharmaceuticals' manufacturing facility in Monroe, North Carolina, U.S. The observations were issued at the end of GMP inspection of facility from June 9-17, the company said in a filing on Wednesday. All the observations are procedural in nature and not related to data integrity. The company said it will work in close collaboration with the regulator to address them and respond to within the stipulated timeline.
The Hindu
5 hours ago
- The Hindu
U.S. FDA issues two observations to Zydus' oncology injectable plant in Ahmedabad
U.S. Food and Drug Administration (FDA) has issued two observations to the oncology injectable plant of Zydus in Ahmedabad. The observations were issued following a GMP follow-up inspection of the facility in SEZ 1, near Matoda from June 9-18. They were not related to data integrity. The company will closely work with the U.S. FDA to address and respond to the observations in an expeditious manner, Zydus said on Wednesday.
